比较一下CRISPR专利内容# Biology - 生物学
P*e
1 楼
今天有空去查了一下CRISPR专利的历史，UCB的专利已经有claim通过了审查（allow）
，只是还没有issue（时间问题）。我在后面列出来了其中一个通过了的claim，同时把
张锋issue了的专利里面的一个claim也列了出来。大家看能避开不？张锋后来的Cpf1看
着能避开UCB的Cas9。
有意思的是发现最早的一篇CRISPR相关专利申请其实是Luciano A. Marraffini（张锋
合作者）在Northwestern University时申请的，priority date Sep 23, 2008，早了
好几年。看看claim，只有interference，还没进化到切割，可惜一个claim也没批，居
然华丽丽的被一堆112给毙了，也就是审查员觉得那专利写的不清不楚，业内普通人士
看着不可能做出claim的结果，连101，102，103都没用上就挂了。西北也是早早的
abandon了，当年连PCT都没申请，可见并不重视。张锋专利里也没有Marraffini，虽然
science文章有他，我猜可能也是他只做真核interference方面的工作吧，张跟他合作
并进化到了cleave。
张锋专利
https://www.google.com/patents/US8697359
其中一个claim
1. A method of altering expression of at least one gene product comprising
introducing into a eukaryotic cell containing and expressing a DNA molecule
having a target sequence and encoding the gene product an engineered, non-
naturally occurring Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPR)—CRISPR associated (Cas) (CRISPR-Cas) system comprising one
or more vectors comprising:
a) a first regulatory element operable in a eukaryotic cell operably linked
to at least one nucleotide sequence encoding a CRISPR-Cas system guide RNA
that hybridizes with the target sequence, and
b) a second regulatory element operable in a eukaryotic cell operably linked
to a nucleotide sequence encoding a Type-II Cas9 protein,
wherein components (a) and (b) are located on same or different vectors of
the system, whereby the guide RNA targets the target sequence and the Cas9
protein cleaves the DNA molecule, whereby expression of the at least one
gene product is altered; and, wherein the Cas9 protein and the guide RNA do
not naturally occur together.
UCB专利：
https://www.google.com/patents/US20140068797?cl=en
UCB 其中一个已经过了的claim，其他通过审查的也很类似，issue只是时间问题。
A method of cleaving a nucleic acid comprising contacting a target DNA
molecule having a target sequence with an engineered and/or non-naturally
occurring Type II CRISPR-CRISPR associated (Cas)(CRISPR-Cas)system
comprising
a) a Cas9 protein; and
b) a single molecule DNA-targeting RNA comprising
i)a targeter_RNA that hybridizes with the target sequence, and
ii)an activator-RNA that hybridizes with the targeter-RNA to form a double-
stranded RNA duplex of a protein-binding segment,
wherein the activator-RNA and the targeter-RNA are covalently linked to one
another with intervening nucleotides,
Wherein the single molecule DNA-targeting RNA forms complex with the Cas9
protein, whereby the single molecule DNA-targeting RNA targets the target
sequence, and the Cas9 protein cleaves the target DNA molecule.
西北专利：
https://www.google.com/patents/US20100076057
Claim 1: A method of inhibiting the function and/or presence of a target DNA
sequence in a eukaryotic cell comprising:
administering crRNA and one or more cas proteins, or nucleic acid sequences
encoding said one or more cas proteins, to a eukaryotic cell comprising a
target DNA sequence, wherein said crRNA hybridizes with said target DNA
sequence thereby interfering with the function and/or presence of said
target DNA sequence.
，只是还没有issue（时间问题）。我在后面列出来了其中一个通过了的claim，同时把
张锋issue了的专利里面的一个claim也列了出来。大家看能避开不？张锋后来的Cpf1看
着能避开UCB的Cas9。
有意思的是发现最早的一篇CRISPR相关专利申请其实是Luciano A. Marraffini（张锋
合作者）在Northwestern University时申请的，priority date Sep 23, 2008，早了
好几年。看看claim，只有interference，还没进化到切割，可惜一个claim也没批，居
然华丽丽的被一堆112给毙了，也就是审查员觉得那专利写的不清不楚，业内普通人士
看着不可能做出claim的结果，连101，102，103都没用上就挂了。西北也是早早的
abandon了，当年连PCT都没申请，可见并不重视。张锋专利里也没有Marraffini，虽然
science文章有他，我猜可能也是他只做真核interference方面的工作吧，张跟他合作
并进化到了cleave。
张锋专利
https://www.google.com/patents/US8697359
其中一个claim
1. A method of altering expression of at least one gene product comprising
introducing into a eukaryotic cell containing and expressing a DNA molecule
having a target sequence and encoding the gene product an engineered, non-
naturally occurring Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPR)—CRISPR associated (Cas) (CRISPR-Cas) system comprising one
or more vectors comprising:
a) a first regulatory element operable in a eukaryotic cell operably linked
to at least one nucleotide sequence encoding a CRISPR-Cas system guide RNA
that hybridizes with the target sequence, and
b) a second regulatory element operable in a eukaryotic cell operably linked
to a nucleotide sequence encoding a Type-II Cas9 protein,
wherein components (a) and (b) are located on same or different vectors of
the system, whereby the guide RNA targets the target sequence and the Cas9
protein cleaves the DNA molecule, whereby expression of the at least one
gene product is altered; and, wherein the Cas9 protein and the guide RNA do
not naturally occur together.
UCB专利：
https://www.google.com/patents/US20140068797?cl=en
UCB 其中一个已经过了的claim，其他通过审查的也很类似，issue只是时间问题。
A method of cleaving a nucleic acid comprising contacting a target DNA
molecule having a target sequence with an engineered and/or non-naturally
occurring Type II CRISPR-CRISPR associated (Cas)(CRISPR-Cas)system
comprising
a) a Cas9 protein; and
b) a single molecule DNA-targeting RNA comprising
i)a targeter_RNA that hybridizes with the target sequence, and
ii)an activator-RNA that hybridizes with the targeter-RNA to form a double-
stranded RNA duplex of a protein-binding segment,
wherein the activator-RNA and the targeter-RNA are covalently linked to one
another with intervening nucleotides,
Wherein the single molecule DNA-targeting RNA forms complex with the Cas9
protein, whereby the single molecule DNA-targeting RNA targets the target
sequence, and the Cas9 protein cleaves the target DNA molecule.
西北专利：
https://www.google.com/patents/US20100076057
Claim 1: A method of inhibiting the function and/or presence of a target DNA
sequence in a eukaryotic cell comprising:
administering crRNA and one or more cas proteins, or nucleic acid sequences
encoding said one or more cas proteins, to a eukaryotic cell comprising a
target DNA sequence, wherein said crRNA hybridizes with said target DNA
sequence thereby interfering with the function and/or presence of said
target DNA sequence.
